At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
GLS-1027 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
In Brief
A Phase 2 clinical trial evaluating GLS-1027 and Placebo for Pneumonitis and SARS-CoV Infection. Completed, enrolled 132 participants across 17 sites in 5 countries.
Detailed Summary
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonitis, SARS-CoV Infection
CountriesBulgaria, North Macedonia, Puerto Rico, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartMay 2021
Primary CompletionAug 2022
Study CompletionJul 2023
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartMay 7, 2021
Primary CompletionAug 14, 2022
Study CompletionJul 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.7 years ago
Interventions
GLS-1027drug
GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
Placebodrug
Placebo looks like GLS-1027